stockrow
Friday 6 November 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
31.60
2.02
+6.83%
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) EBITDA
Cogent Biosciences, Inc.'s EBITDA for fiscal 2025 was −$332.2M, compared with −$281.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$388.7M. Over the past ten years it has ranged from −$332.2M (fiscal 2025) to −$6.4M (fiscal 2015) — the current reading is the lowest in ten years. EBITDA has fallen for 4 consecutive fiscal years. Cogent Biosciences, Inc. ranks 563rd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$332.2M | — |
| FY2024 | −$281.1M | — |
| FY2023 | −$211.0M | — |
| FY2022 | −$148.6M | — |
| FY2021 | −$75.4M | — |
| FY2020 | −$81.5M | — |
| FY2019 | −$30.9M | — |
| FY2018 | −$34.9M | — |
| FY2017 | −$25.0M | — |
| FY2016 | −$18.2M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$102.6M | — |
| Mar 2026 | −$103.9M | — |
| Dec 2025 | −$99.7M | — |
| Sep 2025 | −$82.6M | — |
| 34 more quarters | Free account |
Against its own ten years
Low −$332.2M
High −$6.4M
Ten-year median
−$75.4M
Current reading's percentile
9
EBITDA against peers
| Company | EBITDA |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $191.8M |
| TVTX Travere Therapeutics, Inc. compare | −$83.5M |
| MANE Veradermics Incorporated compare | −$88.4M |
| CGON CG Oncology, Inc. compare | −$250.7M |
| ERAS Erasca, Inc. compare | −$302.6M |
| COGT Cogent Biosciences, Inc. | −$388.7M |
| SRRK Scholar Rock Holding Corporation compare | −$405.8M |
| CRSP CRISPR Therapeutics AG compare | −$513.8M |
| IMVT Immunovant, Inc. compare | −$565.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on COGT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement